id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC10694292
core_pubmed_pmc
Increased sinusoidal export of drug glucuronides is a compensative mechanism in liver cirrhosis of mice
Increased sinusoidal export of drug glucuronides is a compensative mechanism in liver cirrhosis of mice Abstract Rationale: Liver cirrhosis is known to affect drug pharmacokinetics, but the functional assessment of the underlying pathophysiological alterations in drug metabolism is difficult. Methods: Cirrhosis in mice...
PMC2889891
core_pubmed_pmc
Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel
Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel Abstract Abstract Background We have studied the in vitro and in vivo utility of polyethylene glycol (PEG)-hydrogels for the development of an anticancer drug 5-fluorouracil (5-FU) delivery system. Methods A 5-FU-loaded PEG-hydr...
PMC4709389
core_pubmed_pmc
Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach
Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach Abstract Abstract Purpose Acotiamide, a gastroprokinetic agent used to treat functional dyspepsia, is tran...
PMC8023329
core_pubmed_pmc
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant Abstract Abstract Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed th...
PMC7540321
core_pubmed_pmc
Physiological parameter values for physiologically based pharmacokinetic models in food‐producing animals. Part I: Cattle and swine
Physiological parameter values for physiologically based pharmacokinetic models in food‐producing animals. Part I: Cattle and swine Abstract Abstract Physiologically based pharmacokinetic (PBPK) models for chemicals in food animals are a useful tool in estimating chemical tissue residues and withdrawal intervals. Physi...
PMC11597430
core_pubmed_pmc
An In Silico Approach to Discover Efficient Natural Inhibitors to Tie Up Epstein–Barr Virus Infection
An In Silico Approach to Discover Efficient Natural Inhibitors to Tie Up Epstein–Barr Virus Infection Abstract Epstein–Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. EBV is a widespread virus and causes infectious mononucleosis, which manifests with symptoms such as fever, ...
PMC7679260
core_pubmed_pmc
Antispasmodic effects of the essential oil of Croton zehnteneri , anethole, and estragole, on tracheal smooth muscle
Antispasmodic effects of the essential oil of Croton zehnteneri , anethole, and estragole, on tracheal smooth muscle Abstract Croton zehntneri is a plant well adapted to the semi-arid climate of northeastern region of Brazil. The essential oil of C. zehntneri (EOCz) has been described to have several pharmacologic prop...
PMC11576624
core_pubmed_pmc
Assessing the performance of QSP models: biology as the driver for validation
Assessing the performance of QSP models: biology as the driver for validation Abstract Validation of a quantitative model is a critical step in establishing confidence in the model’s suitability for whatever analysis it was designed. While processes for validation are well-established in the statistical sciences, the f...
PMC7529773
core_pubmed_pmc
Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells
Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells Abstract Abstract In vivo pharmacokinetics (PK) studies using mice and monkeys are the main approaches for evaluating and predicting the PK of antibodies, and there is a strong demand for me...
PMC3933742
core_pubmed_pmc
Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues
Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues Abstract Citicoline is the generic name of the pharmaceutical substance that chemically is cytidine-5′-diphosphocholine (CDP-choline), which is identical to the natural intracellular precursor of phospholipid phosphatidylcholine. Following in...
PMC12061681
core_pubmed_pmc
Tacrolimus exposure during the three-month period following allogeneic stem cell transplantation predicts overall survival
Tacrolimus exposure during the three-month period following allogeneic stem cell transplantation predicts overall survival Abstract Abstract Objectives The objective of this study was to investigate the relationship between both short-term and long-term tacrolimus exposure and overall survival after allogeneic stem cel...
PMC6270898
core_pubmed_pmc
Trends in Protein-Based Biosensor Assemblies for Drug Screening and Pharmaceutical Kinetic Studies
Trends in Protein-Based Biosensor Assemblies for Drug Screening and Pharmaceutical Kinetic Studies Abstract Abstract The selection of natural and chemical compounds for potential applications in new pharmaceutical formulations constitutes a time-consuming procedure in drug screening. To overcome this issue, new devices...
PMC8605568
core_pubmed_pmc
Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China
Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China Abstract Background The variation of drug responses and target does among individuals is mostly determined by genes. With the development of pharmacogenetics and pharmacogenomics, the differences in drug response between...
PMC6814631
core_pubmed_pmc
Development of In Vitro – In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
Development of In Vitro – In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation Abstract Abstract Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis. Upadacitinib was evaluated in Phase 3 stud...
PMC5055906
core_pubmed_pmc
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs Abstract Purpose AST-120 is used to decrease the abundance of serum uremic toxins in treatment of chronic kidney disease; however, it could also adsorb conco...
PMC9706570
core_pubmed_pmc
A Reactive Oxygen Species-Scavenging ‘Stealth’ Polymer, Poly(thioglycidyl glycerol), Outperforms Poly(ethylene glycol) in Protein Conjugates and Nanocarriers and Enhances Protein Stability to Environmental and Biological Stressors
A Reactive Oxygen Species-Scavenging ‘Stealth’ Polymer, Poly(thioglycidyl glycerol), Outperforms Poly(ethylene glycol) in Protein Conjugates and Nanocarriers and Enhances Protein Stability to Environmental and Biological Stressors Abstract Abstract This study addresses well-known shortcomings of poly(ethylene glycol) (...
PMC12615732
core_pubmed_pmc
A large-scale human toxicogenomics resource for drug-induced liver injury prediction
A large-scale human toxicogenomics resource for drug-induced liver injury prediction Abstract Abstract Drug-Induced Liver Injury (DILI) remains one of the most critical challenges in drug development, causing patient safety concerns, clinical trial failures and drug withdrawals. We introduce ToxPredictor , a toxicogeno...
PMC5604705
core_pubmed_pmc
Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis Abstract Abstract Objective To evaluate safety, pharmacokinetics and pharmacodynamics of anti-interferon (IFN)-γ monoclonal antibody AMG 811 in subjects with SLE without or...
PMC12165791
core_pubmed_pmc
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients Abstract BACKGROUND Tebentafusp is the first T cell receptor–based bispecific protein approved for clinical use in HLA-A*02:01 + adult patients with unresectable/metastatic uveal melanoma. It redirects T cell...
PMC6017738
core_pubmed_pmc
A Comparative Pharmacokinetic Study by UHPLC-MS/MS of Main Active Compounds after Oral Administration of Zushima-Gancao Extract in Normal and Adjuvant-Induced Arthritis Rats
A Comparative Pharmacokinetic Study by UHPLC-MS/MS of Main Active Compounds after Oral Administration of Zushima-Gancao Extract in Normal and Adjuvant-Induced Arthritis Rats Abstract A sensitive and rapid ultra high-performance liquid-chromatography tandem mass spectrometry (UHPLC-MS/MS) method has been applied to inve...
PMC9401557
core_pubmed_pmc
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors Abstract Abstract Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector re...
PMC11943233
core_pubmed_pmc
Pharmacokinetic–Pharmacodynamic Simulation of Muscle Relaxation Antagonistic Conditions for Post-Operative Recurarization Prevention
Pharmacokinetic–Pharmacodynamic Simulation of Muscle Relaxation Antagonistic Conditions for Post-Operative Recurarization Prevention Abstract Abstract Background/Objectives: No study has simulated rocuronium (Rb) effect-site concentrations (Ce_Rb) using real-time data—such as Rb concentrations, train-of-four (TOF) coun...
PMC6200719
core_pubmed_pmc
Imaging of Pseudomonas aeruginosa infection with Ga-68 labelled pyoverdine for positron emission tomography
Imaging of Pseudomonas aeruginosa infection with Ga-68 labelled pyoverdine for positron emission tomography Abstract Abstract Pseudomonas aeruginosa is an increasingly prevalent opportunistic pathogen that causes a variety of life-threatening nosocomial infections. Novel strategies for the development of new antibacter...
PMC10187420
core_pubmed_pmc
Transcriptomic signature, bioactivity and safety of a non-hepatoxic analgesic generating AM404 in the mid-brain PAG region
Transcriptomic signature, bioactivity and safety of a non-hepatoxic analgesic generating AM404 in the mid-brain PAG region Abstract Abstract The safe and effective management of pain is a critical healthcare and societal need. The potential for misuse and addiction associated with opioids, nephrotoxicity, and gastroint...
PMC11881576
core_pubmed_pmc
Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD
Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD Abstract ABSTRACT Eravacycline is a broad-spectrum fluorocycline currently approved for complicated intra-abdominal infections (cIAIs). In lung-infection models, it is effective aga...
PMC6579883
core_pubmed_pmc
Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens
Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens Abstract An important application of time-kill curve (TKC) assays is determination of the nature of the best PK/PD index ( f AUC/MIC or f T% > MIC) and its target value for predicting clinical effic...
PMC5407619
core_pubmed_pmc
Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice
Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice Abstract The purpose of this work was to use various molecular imaging techniques to non-invasively assess GSK2849330 (anti HER3 ADCC an...
PMC9296590
core_pubmed_pmc
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women Abstract Aims Transgender women (TGW) have been underrepresented in trials and use gender‐affirming hormonal therapies (GAHT) that may alter renal function by significantly increasing creatinine clearance. Populat...
PMC12479631
core_pubmed_pmc
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic–Pharmacoeconomic Evaluation
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic–Pharmacoeconomic Evaluation Abstract Abstract Background The increasing use of immune checkpoint inhibitors, such as durvalumab, places a significant financial burden on healthcare systems, strains hospital capac...
PMC4580629
core_pubmed_pmc
Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A
Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A Abstract To investigate the auto-induction of cytochrome P450 (CYP450) by Chloroxoquinoline (CXL), a novel anticancer drug. Three experiments related to the induction of CYP450 were performed: a) In vitro use...
PMC4769423
core_pubmed_pmc
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848 Abstract Abstract Background Many patients with asthma have a T-helper type 2 (Th2) driven inflammation of the lung, whereas toll-like receptor 7 (TLR7) agonists, by inducing type I interferons, inhibit Th2 responses. In man, oral or...
PMC12057358
core_pubmed_pmc
Distribution of ganciclovir in the porcine central nervous system
Distribution of ganciclovir in the porcine central nervous system Abstract ABSTRACT Ganciclovir is often used compassionately for encephalitis due to cytomegalovirus (CMV) and human herpes virus 6b (HHV-6b). Ganciclovir pharmacokinetic studies in the central nervous system (CNS) generally rely on single measurements in...
PMC8705537
core_pubmed_pmc
Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia
Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia Abstract Total-body irradiation (TBI) based conditioning prior to allogeneic hematopoietic stem cell transplantation (HSCT) is generally regarded as the gold-standard for ch...
PMC6471806
core_pubmed_pmc
Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children Abstract Abstract Background The World Health Organization (WHO) recommends combinations of an artemisinin derivative plus an anti-malarial drug ...
PMC5045556
core_pubmed_pmc
Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice
Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice Abstract Abstract We have shown recently that concurrent harmaline, a monoamine oxidase-A inhibitor (MAOI), potentiates serotonin (5-HT) receptor agonist 5-methoxy- N,N -dime...
PMC12848337
core_pubmed_pmc
Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies
Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies Abstract Key Points • Rogocekib (CTX-712), a pan–CDC2-like kinase inhibitor, showed tolerable safety in relapsed/refractory AML and higher-risk MDS. • The overall response rate was 42.9%, with promising activity in patients, inc...
PMC6071124
core_pubmed_pmc
Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Abstract Simple Summary Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of...
PMC7768337
core_pubmed_pmc
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia Abstract PURPOSE Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic ...
PMC10820197
core_pubmed_pmc
Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units
Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units Abstract Abstract The pediatric population exhibits an important age-dependent heterogeneity in pharmacokinetics and pharmacodynamics parameters, resulting in differences in drug efficacy and toxicity compare...
PMC7831558
core_pubmed_pmc
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges Abstract Highlights • Chloroquine (CQ) has in vitro evidence of potential efficacy against SARS-CoV-2 (virus causing COVID-19) and particularly effective at early stages of infection when viral load is low. • CQ can achieve mi...
PMC12136075
core_pubmed_pmc
Anti-Tyrosinase and Radical Scavenging Activities of Selected Cassipourea Plants and Isolated 7-Methoxygeranin A: Traditional Use as Skin Lighteners
Anti-Tyrosinase and Radical Scavenging Activities of Selected Cassipourea Plants and Isolated 7-Methoxygeranin A: Traditional Use as Skin Lighteners Abstract Abstract Background In rural areas of KwaZulu-Natal and Eastern Cape Provinces, South Africa, women have traditionally used bark extracts from Cassipourea flanaga...
PMC4964175
core_pubmed_pmc
SCISSOR—Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol
SCISSOR—Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol Abstract Introduction The approved analgesic and anti-inflammatory drugs ibuprofen and indometacin block the small GTPase RhoA, a key enzyme that impedes axonal sprouting after axonal damage. Inhibition of the Rho pathw...
PMC7843372
core_pubmed_pmc
Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient Abstract Abstract Background With the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug...
PMC9103606
core_pubmed_pmc
Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation
Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation Abstract Abstract Background and Objective Hydroxychloroquine was widely used during the severe acute respiratory syndrome coronavirus 2 pandemic as an antiviral drug. Most previous pharmacokinetic/pharmacodynamic studies...
PMC6820606
core_pubmed_pmc
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting Abstract Purpose To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial ...
PMC9021690
core_pubmed_pmc
Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?
Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation? Abstract Abstract Busulfan has high intra-individual variability and possible time-dependent changes in clearance, which...
PMC12649303
core_pubmed_pmc
A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application to Paracetamol and Its Metabolite
A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application to Paracetamol and Its Metabolite Abstract Abstract A preterm and term neonate to adult (PTNA) maturation equation was introduced recently to describe the glomerular filtration rate maturation from birth t...
PMC3404091
core_pubmed_pmc
Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model Abstract Abstract Introduction Continued pressure from glycopeptide use has led to non-susceptible strains of Staphylococcus aureus including heterogeneously vancomycin-intermediate S. aureus (hVI...
PMC11020314
core_pubmed_pmc
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis Abstract Abstract Background To perform a systematic review with meta-analysis with the dual intent of...
PMC6971844
core_pubmed_pmc
Mobilized peripheral blood: an updated perspective
Mobilized peripheral blood: an updated perspective Abstract Enforced egress of hematopoietic stem cells (HSCs) out of the bone marrow (BM) into the peripheral circulation, termed mobilization, has come a long way since its discovery over four decades ago. Mobilization research continues to be driven by the need to opti...
PMC8585822
core_pubmed_pmc
Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients Abstract Abstract Introduction Intramuscular paromomycin monotherapy to treat visceral leishmaniasis (VL) has been shown to be effective for Indian patients, ...
PMC8915826
core_pubmed_pmc
Evaluation of Inhalation Exposures and Potential Health Impacts of Ingredient Mixtures Using in vitro to in vivo Extrapolation
Evaluation of Inhalation Exposures and Potential Health Impacts of Ingredient Mixtures Using in vitro to in vivo Extrapolation Abstract Abstract In vitro methods offer opportunities to provide mechanistic insight into bioactivity as well as human-relevant toxicological assessments compared to animal testing. One of the...
PMC7297490
core_pubmed_pmc
Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations Abstract Prostacyclin pathway agents are a critical treatment for patients with pulmonary arterial hypertension. Seven prostacyclin pathway agents are available, including agents administered by paren...
PMC6916274
core_pubmed_pmc
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers Abstract Abstract Restriction of iron availability by ferroportin inhibition is a novel approach to treating non‐transfusion‐dependent thalassemia (β‐thalassemia intermedia). This first‐in‐human, Phase I study ( https://www.clinica...
PMC12830148
core_pubmed_pmc
Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations
Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations Abstract Key Points • Interpatient differences in hydroxyurea dosing for children with SCA are predicted by drug PK. • Hydroxyurea PK parameters in children with SCA from the United States, Africa, and the Caribbean pre...
PMC10519932
core_pubmed_pmc
Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment
Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment Abstract This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model to predict the maximum plasma concentration (C max ...
PMC12588651
core_pubmed_pmc
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis Abstract Supplemental Digital Content is Available in the Text. Key Words: expert clinical pharm...
PMC9545781
core_pubmed_pmc
Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein
Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein Abstract Abstract XBD173 and etifoxine are translocator protein (TSPO) ligands that modulate inflammatory responses in preclinical models. Limited human pharmacokinetic data is availab...
PMC12177174
core_pubmed_pmc
A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055
A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055 Abstract Summary Excessive Wnt signaling contributes to the development of fibrotic diseases and cancer. Here, we report the findings of a phase 1 study evaluating AZD5055, an orally administered porcupine inhi...
PMC6422639
core_pubmed_pmc
Under‐representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database
Under‐representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database Abstract Abstract Aims To evaluate the availability of pharmacokinetic, safety and efficacy analyses specifically targeted at elderly, prior to the authorization of drugs. Metho...
PMC10810027
core_pubmed_pmc
Real-Time Imaging of Single Retinal Cell Apoptosis in a Non-Human Primate Ocular Hypertension Model
Real-Time Imaging of Single Retinal Cell Apoptosis in a Non-Human Primate Ocular Hypertension Model Abstract Purpose To evaluate the feasibility of using DARC (detection of apoptosing retinal cells) technology as a biomarker for preclinical assessment of glaucomatous damage in a non-human primate (NHP) model of ocular ...
PMC5991393
core_pubmed_pmc
Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats
Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats Abstract Abstract 4′-cyano-2′-deoxyinosine (SK14-061a), a novel nucleoside analog based on inosine, has antiviral activity against the human immunodeficiency virus type 1 that has the ability to acquire res...
PMC12070208
core_pubmed_pmc
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study Abstract Background/Aims Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab tro...
PMC5076779
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole Abstract Background: The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) formulation of delayed-release dexlansoprazole 30 mg was evaluated versus the dexlansoprazole 30 mg capsule...
PMC3912854
core_pubmed_pmc
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics Abstract Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can ...
PMC12845319
core_pubmed_pmc
Clinical Characteristics, Long-Term Pharmacokinetics, and Outcomes in Kidney Transplant Recipients from an African Tertiary Centre: A 10-Year Single-Centre Retrospective Review
Clinical Characteristics, Long-Term Pharmacokinetics, and Outcomes in Kidney Transplant Recipients from an African Tertiary Centre: A 10-Year Single-Centre Retrospective Review Abstract Background: Kidney transplantation outcomes in resource-limited settings remain underreported. This 10-year retrospective review exami...
PMC9280727
core_pubmed_pmc
Micelles as potential drug delivery systems for colorectal cancer treatment
Micelles as potential drug delivery systems for colorectal cancer treatment Abstract Abstract Despite the significant progress in cancer therapy, colorectal cancer (CRC) remains one of the most fatal malignancies worldwide. Chemotherapy is currently the mainstay therapeutic modality adopted for CRC treatment. However, ...
PMC3460023
core_pubmed_pmc
Pharmacokinetics of cyclosporin - a microemulsion in children with idiopathic nephrotic syndrome
Pharmacokinetics of cyclosporin - a microemulsion in children with idiopathic nephrotic syndrome Abstract Abstract OBJECTIVE: We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between...
PMC6057249
core_pubmed_pmc
Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study
Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study Abstract Abstract Background & objectives: There is little information concerning intravenously (i.v.) administered colistin in patients with multidrug-resistant (MDR) Gram-negative infections. Thus, this pilot pro...
PMC9525106
core_pubmed_pmc
Intestinal permeability of agaro-oligosaccharides: Transport across Caco-2 cell monolayers and pharmacokinetics in rats
Intestinal permeability of agaro-oligosaccharides: Transport across Caco-2 cell monolayers and pharmacokinetics in rats Abstract Abstract Agaro-oligosaccharides (AOSs), even-numbered oligosaccharides prepared from agar, are applied to various food, including supplements, drinks, and jellies because of their biological ...
PMC3388254
core_pubmed_pmc
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152) Abstract Summary Introduction Modeling and simulation of pharmacokinetics and pharmacodynamics has previously been shown to be potentially useful in designing Phase I programs of novel ant...
PMC12108447
core_pubmed_pmc
Impact of Timing of Beta-Lactam Therapeutic Drug Monitoring and Therapy Adjustment in Critically Ill Patients
Impact of Timing of Beta-Lactam Therapeutic Drug Monitoring and Therapy Adjustment in Critically Ill Patients Abstract Purpose: To assess the impact of beta-lactam therapeutic drug monitoring (TDM) timing and therapy adjustment on clinical cure and 30-day mortality. Methods: This was a prospective study of critically i...
PMC8144741
core_pubmed_pmc
Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial
Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial Abstract Background Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF) combination is approved for HIV pre-exposure...
PMC5871563
core_pubmed_pmc
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study Abstract Summary Background Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%...
PMC11054797
core_pubmed_pmc
Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example
Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example Abstract Abstract Midazolam, a short-acting benzodiazepine, is widely used to alleviate patient anxiety, enhance compliance, and aid in anesthesia. While its side effects are typically dose-dependent and manageable with vigilan...
PMC6899822
core_pubmed_pmc
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects Abstract Abstract GW Pharmaceuticals’ formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associa...
PMC3043256
core_pubmed_pmc
Marginal increase of sunitinib exposure by grapefruit juice
Marginal increase of sunitinib exposure by grapefruit juice Abstract Purpose The drug label of sunitinib includes a warning for concomitant use of grapefruit juice (GJ) but clinical evidence for this drug interaction is lacking. The aim of this study is to determine the effect of GJ, a potent intestinal cytochrome P450...
PMC4386948
core_pubmed_pmc
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications Abstract AIM Drug–drug interactions between antimalarial and antiretroviral drugs may influence antimalarial treatment outcomes. The aim of this study was to investigate the potential drug–drug interactio...
PMC6864662
core_pubmed_pmc
Comparative Pharmacokinetics of Gallic Acid, Protocatechuic Acid, and Quercitrin in Normal and Pyelonephritis Rats after Oral Administration of a Polygonum capitatum Extract
Comparative Pharmacokinetics of Gallic Acid, Protocatechuic Acid, and Quercitrin in Normal and Pyelonephritis Rats after Oral Administration of a Polygonum capitatum Extract Abstract Polygonum capitatum Buch.-Ham. ex D. Don is traditionally used by Hmong for the treatment of urinary tract infections and pyelonephritis....
PMC4186453
core_pubmed_pmc
Use of a novel rapid and resource-efficient cassette dosing approach to determine the pharmacokinetics and CNS distribution of small molecule 7-transmembrane receptor allosteric modulators in rat
Use of a novel rapid and resource-efficient cassette dosing approach to determine the pharmacokinetics and CNS distribution of small molecule 7-transmembrane receptor allosteric modulators in rat Abstract Approaches to efficiently and accurately define the pharmacokinetics (PK) of large sets of small molecules in roden...
PMC2809247
core_pubmed_pmc
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans Abstract Abstract Background Data from retrospective studies have suggested that there may be an interaction between fluconazole and nevirapine, increasing nevirapine concentrations and potentially leading to hepatotoxicity. M...
PMC10222464
core_pubmed_pmc
Pharmacokinetic Study and Metabolite Identification of CAM106 in Rats by Validated UHPLC-MS/MS
Pharmacokinetic Study and Metabolite Identification of CAM106 in Rats by Validated UHPLC-MS/MS Abstract Given the limitations of existing antiviral drugs and vaccines, there is still an urgent need for new anti-influenza drugs. CAM106, a rupestonic acid derivative, was studied for its potent antiviral activity and show...
PMC5642551
core_pubmed_pmc
A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients Abstract Aim The purpose of the current study was to investigate individualized therapy of tacrolimus (Tac), as well as complications after liver transplantation (LT) wi...
PMC10204800
core_pubmed_pmc
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats Abstract Introduction: An active metabolite of buprenorphine ( BUP ), called norbuprenorphine ( NorBUP ), is implicated in neonatal opioid withdrawal syndrome when BUP is...
PMC12599041
core_pubmed_pmc
The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test
The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test Abstract Background The gut microbiota is known to influence levodopa metabolism in the intestinal tract, primarily through the action of tyrosine decarboxylase, an enzyme encoded by the tyrosine dec...
PMC4875923
core_pubmed_pmc
Significant Pharmacokinetic Interactions Between Quinine and Ampicillin–Cloxacillin Combination
Significant Pharmacokinetic Interactions Between Quinine and Ampicillin–Cloxacillin Combination Abstract Introduction The co-existence of malaria with bacterial infections is common in the tropics, hence the concurrent use of antimalarials and antibiotics. Objective This study aimed to investigate the effect on pharmac...
PMC6175414
core_pubmed_pmc
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects Abstract Abstract Continuous glucose monitoring (CGM) systems allow patients with diabetes mellitus to closely track glucose concentrations over several days, identify trends in gluc...
PMC6839502
core_pubmed_pmc
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects Abstract PF-06751979 is a selective inhibitor of the beta-site amyloid precursor protein cleaving enzyme-1, which is ...
PMC8877499
core_pubmed_pmc
Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients
Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients Abstract Abstract The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung transplant recipients, to explore its covariates, and to propose an individualized dosing regimen. Ganci...
PMC5516238
core_pubmed_pmc
Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions
Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions Abstract Abstract The dissolution, intestinal absorption and presystemic metabolism of a drug depend on its physicochemical characteristics but also on numerous physiological (e.g. gastrointestinal pH, v...
PMC7759025
core_pubmed_pmc
Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4 th Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking
Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4 th Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking Abstract Background COVID-19 caused by SARS-CoV-2 infection has been spreading through many countries since the end of 2019. The 4...
PMC7254798
core_pubmed_pmc
Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies
Insight into the Loading and Release Properties of MCM-48/Biopolymer Composites as Carriers for 5-Fluorouracil: Equilibrium Modeling and Pharmacokinetic Studies Abstract Abstract The effect of the integration between MCM-48 and some biopolymers (starch, chitosan, and β-cyclodextrin) on enhancing the pharmaceutical prop...
PMC7142887
core_pubmed_pmc
Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review
Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review Abstract Abstract The treatment of invasive fungal infections remains challenging and the emergence of new fungal pathogens as well as the development of resistance to the main antifungal drugs highlight ...
PMC10196430
core_pubmed_pmc
Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions Abstract Abstract The immunosuppressant and narrow therapeutic index drug tacrolimus is metabolized mainly via cytochrome P450 (CYP) 3A4 and CYP3A5. For its pharmacokinetics (PK), high inter‐ and ...
PMC11772993
core_pubmed_pmc
The graded heat-health risk forecast and early warning with full-season coverage across China: a predicting model development and evaluation study
The graded heat-health risk forecast and early warning with full-season coverage across China: a predicting model development and evaluation study Abstract Summary Background Due to global climate change, high temperature and heatwaves have become critical issues that pose a threat to human health. An effective early w...
PMC3414211
core_pubmed_pmc
Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption
Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption Abstract Background Lipid-based liquid crystalline nanoparticles (LCNPs) have attracted growing interest as novel drug-delivery systems for improving the bioavailabilit...
PMC7496896
core_pubmed_pmc
Regional Differences in Penetration of the Protein Stabilizer Trimethoprim (TMP) in the Rat Central Nervous System
Regional Differences in Penetration of the Protein Stabilizer Trimethoprim (TMP) in the Rat Central Nervous System Abstract Abstract Regulating gene expression at the protein level is becoming increasingly important for answering basic questions in neurobiology. Several techniques using destabilizing domains (DD) on tr...
PMC9774644
core_pubmed_pmc
Population Pharmacokinetic Analysis Proves Superiority of Continuous Infusion in PK/PD Target Attainment with Oxacillin in Staphylococcal Infections
Population Pharmacokinetic Analysis Proves Superiority of Continuous Infusion in PK/PD Target Attainment with Oxacillin in Staphylococcal Infections Abstract Considering its very short elimination half-life, the approved oxacillin dosage might not be sufficient to maintain the pharmacokinetic/pharmacodynamics (PK/PD) t...
PMC10711279
core_pubmed_pmc
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine Abstract Abstract Recently, the Amazonian plant medicine “ayahuasca”—containing the psychedelic compound N,N-dimethyltryptamine (DMT) and numerous β-carbolin...
PMC9393097
core_pubmed_pmc
Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients
Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients Abstract Purpose The purpose of this study was to characterize the population-based pharmacokinetic (POP-PK) profile of imipenem in Vietnamese adult patients and to assess the probability of target attainment (PTA)...